Keith Hamel is a Director at AbbVie, whose known portfolio counts 16 companies.
Is Keith Hamel a fit for your startup?
Paste your website. AI checks the fit and scores every other investor too.
Investment focus
- Sector
- Healthcare
Contacts
Affiliated funds' portfolios
Director at AbbVie, whose known portfolio counts 16 companies
- Zag Bio
- Carisma Therapeutics
- Third Arc Bio
- Accent Therapeutics
- DISCO Pharmaceuticals
- Jnana Therapeutics
- Oisin Biotechnologies
- Soufflé Therapeutics
- Syndeio Biosciences
- Light Horse Therapeutics
- BaseLaunch
- Cephagenix
- and 4 more
Investor Profile
Keith Hamel is listed against sector Healthcare, and focus areas Biotech, Cell & Gene, Drug Discovery and Genomics in the database.
Stage-wise, the deals at AbbVie cluster around Growth, Seed and Series A rounds.
What the affiliated firm has backed is the closest available signal on whether Keith Hamel is worth approaching.
Colleagues at AbbVie
Michael Widmann
Associate Director, Portfolio Strategy & Analytics
Chicago, United States
Mayara Doile
Senior Executive
São Paulo, Brazil
Wenwen He
Venture Capital
United States
Tatiana W
Investor & Partner
United States
Christine Hsieh
Venture Partner
Boston, United States
Kevin Ho
Director, Business Development & Acquisitions
San Francisco, United States
Andrew Little
Investor
Boston, United States
Doug Faunce
Executive Director
Irvine, United States
Frequently asked questions
Who is Keith Hamel?
Keith Hamel is a corporate venture investor based in Chicago, Illinois, United States, listed as Director at AbbVie. The known portfolio of that firm counts 16 companies. That portfolio belongs to the firm, not to Keith Hamel personally.
What does Keith Hamel invest in?
Listed sectors include Healthcare; listed focus areas include Biotech, Cell & Gene, Drug Discovery and Genomics. Those tags come from the portfolios of the firms this profile is attached to, so they read as a record of what has been backed rather than a stated preference for what comes next.
What stage does Keith Hamel invest at?
AbbVie appears in Growth, Seed and Series A rounds across its known deals, and Keith Hamel is listed there as Director. Stage is the strongest single filter when you build a target list: an investor with no record at your stage rarely starts with you.
Which firm is Keith Hamel listed at?
Keith Hamel is listed as Director at AbbVie. 8 other people in the database share a firm with Keith Hamel.
How do I contact Keith Hamel?
A LinkedIn page is on file for Keith Hamel. It is readable inside RaiseHunt after you create an account. The database holds no email address and no phone number for this profile.
Skip the browsing. Let AI find your ideal investors in one minute.
Paste your startup website and AI picks your best-fit investors out of 135,000+ profiles.
Data: RaiseHunt investor dataset · Snapshot 5 September 2026 · How this data is built · Report a correction or request removal